Recent Developments in Bifidobacterium Treatment

Probiotics, defined as live or attenuated bacterial or bacterial products that exerts health effects beyond inherent basic nutrition, have the potential to provide a clinical benefit to the host. The most widely used probiotics in humans are bifidobacteria and others. This paper will review the most recently published literatures that demonstrated the therapeutic benefits of bifidobacterium in patients with active ulcerative colitis including recurrent or refractory pouclitis. In addition, studies that evaluated the response of irritable bowel syndrome to probiotic preparation have also been reviewed. Short term synbiotic (containing B. longum and synergy 1) treatment of active ulcerative colitis results in improvement of the clinical appearance of chronic inflammation in patients receiving this therapy.